Zeaxanthin reduces risk for AMD

St. Louis-based ZeaVision, LLC announced that three recent groundbreaking studies demonstrate that Zeaxanthin (zee-uh-zan-thin), the predominate protective pigment in the back of the eye, reduces the risk for Age-Related Macular Degeneration (AMD) and benefits the treatment of advanced AMD, a condition that destroys central vision and affects millions of Americans. AMD is the leading cause of blindness in people over age 55, according to the American Optometric Association and the incidence of AMD is expected to triple by 2025. The Centers for Disease Control and Prevention (CDC) estimates 7.3 million people are at risk for vision loss resulting from AMD.

In 2011, two studies in Europe and Asia demonstrate that Zeaxanthin lowers AMD risk. A study from the Erasmus Medical Center Rotterdam in the Netherlands demonstrates that nutrients - specifically dietary Zeaxanthin - reduce the risk of early AMD. The Beijing Tongren Eye Center in China recently published data indicating a direct correlation between higher blood serum levels of Zeaxanthin and a 96% reduction of developing AMD. The third and most recent study in the US, from the Retina Center of St. Louis, shows that an additional 20 mg/per day of Zeaxanthin to patients undergoing therapy for advanced or wet AMD significantly reduces the number of invasive treatment cycles required.

While Zeaxanthin is naturally found in the macula as the primary protective carotenoid, it is difficult to replenish through the average daily diet. For example, one would have to eat approximately 20 ears of corn to get a recommended dosage of 8-10 mg of natural dietary Zeaxanthin per daily serving. ZeaVision's EyePromise® brand of all-natural nutraceuticals includes patented formulas that contain the highest daily doses of Zeaxanthin available derived from paprika peppers.